Revance Therapeutics (Revance Therapeutics) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 22, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Revance Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Revance Therapeutics's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Revance Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.

Revance Therapeutics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (Revance Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

RTI:Germany

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Executives

Dwight Moxie	officer: SVP, GC & Secretary	7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley	director	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke	officer: Chief Financial Officer	7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja	director	C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts	officer: President	7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin	director	C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud	director	C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne	director, officer: CEO and President	7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche	officer: Principal Financial Officer	7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail	officer: CFO, Seretary & EVP Corp Dev.	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell	officer: SVP, GC & Secretary	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080